CluePoints Appoints Richard Young as Chief Strategy Officer
Richard has previous experience at Medidata, Cmed Group and PAREXEL International. His most recent role was Vice President, Strategy, Clinical Data, at Veeva Systems. Richard has also acted as the Conference Committee Leader for the SCDM Annual Conference for the past three years, and is currently leading their innovations committee. His wealth of experience will ensure CluePoints' continued growth and development as the leading provider of integrated data review software.
To learn more about CluePoints' award-winning solutions, please visit www.cluepoints.com
About CluePoints
CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. We are leveraging the potential of Artificial Intelligence using Advanced Statistics and Machine Learning to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R2), CluePoints is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation, you now have everything you need to adhere with global regulatory guidance. The result is positive clinical development outcomes, increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.
View original content:https://www.prnewswire.com/news-releases/cluepoints-appoints-richard-young-as-chief-strategy-officer-302288016.html
SOURCE CluePoints
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Taylor Morrison Names Jeremy Hampson Division President of Jacksonville
- Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
- Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share